🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab

Recruitingn/aAges 18 Years - anyAllEisai Co., Ltd.
NCT06322667 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * All participants who are treated with lecanemab in routine clinical practice Exclusion Criteria: * None
💊

What it tests

  • No Intervention
📍

Where

3 sites
Eisai trial site 2
Hiroshima, Japan
Eisai trial site 3
Kyoto, Japan
Eisai trial site 1
Tokyo, Japan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy